
    
      PROTOCOL OUTLINE:

      This is a randomized, open label, multicenter study.

      Patients are randomized to receive standard care with immunosuppression (arm I) or standard
      care with or without immunosuppression (no muromonab-CD3 or cyclosporine)(arm II).

      Arm I: Patients receive methylprednisolone IV once daily for 3 days and muromonab-CD3 IV once
      daily for 10 days. Oral cyclosporine is administered twice daily and oral prednisone is
      administered once daily for 1 year.

      Arm II: Patients receive standard care with or without immunosuppression (no muromonab-CD3 or
      cyclosporine).

      Patients are followed for one year.
    
  